Karl-Josef Langen
Forschungszentrum Jülich
Internal medicineRadiologyPathologyMagnetic resonance imagingOncologyNeuroscienceChemistryPositron emission tomographyBiopsyGlioblastomaGliomaFluoroethylBrain tumorTumor progression18F-fluoroethyl-L-tyrosinePseudoprogressionNuclear medicineIn patientRadiation therapyAmino acidMedicine
387Publications
60H-index
9,486Citations
Publications 383
Newest
#1Julia Post (Forschungszentrum Jülich)H-Index: 3
#2Anja Schaffrath (Forschungszentrum Jülich)H-Index: 1
Last. Antje Willuweit (Forschungszentrum Jülich)H-Index: 21
view all 0 authors...
Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1G93A mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1G93A mice. Transgenic mice were treated daily with RD2RD2 or placebo f...
Source
#1Luana Cristina Camargo (Forschungszentrum Jülich)
#2Michael Schöneck (Forschungszentrum Jülich)H-Index: 2
Last. Antje Willuweit (Forschungszentrum Jülich)H-Index: 21
view all 0 authors...
Understanding the physiopathology of Alzheimer's disease (AD) has improved substantially based on studies of mouse models mimicking at least one aspect of the disease. Many transgenic lines have been established, leading to amyloidosis but lacking neurodegeneration. The aim of the current study was to generate a novel mouse model that develops neuritic plaques containing the aggressive pyroglutamate modified amyloid-β (pEAβ) species in the brain. The TAPS line was developed by intercrossing of t...
Source
#1Norbert Galldiks (Forschungszentrum Jülich)H-Index: 46
#2Maximilian Niyazi (LMU: Ludwig Maximilian University of Munich)H-Index: 30
Last. Karl-Josef Langen (Forschungszentrum Jülich)H-Index: 60
view all 4 authors...
Source
#1Eike Steidl (Goethe University Frankfurt)H-Index: 3
#2Karl-Josef LangenH-Index: 60
Last. Gabriele D. Maurer (DKFZ: German Cancer Research Center)H-Index: 6
view all 14 authors...
Perfusion-weighted MRI (PWI) and O-(2-[18F]fluoroethyl-)-l-tyrosine ([18F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [18F]FET PET. We evalu...
1 CitationsSource
#1Francesco Cicone (Magna Græcia University)H-Index: 13
#1Francesco Cicone (Magna Græcia University)H-Index: 1
Source
#1Martin KocherH-Index: 34
#2Christiane JockwitzH-Index: 12
Last. Svenja CaspersH-Index: 29
view all 14 authors...
Cognitive deficits are common in glioma patients following multimodality therapy, but the relative impact of different types and locations of treatment-related brain damage and recurrent tumors on cognition is not well understood. In 121 WHO Grade III/IV glioma patients, structural MRI, O-(2-[18F]fluoroethyl)-L-tyrosine FET-PET, and neuropsychological testing were performed at a median interval of 14 months (range, 1–214 months) after therapy initiation. Resection cavities, T1-enhancing lesions,...
Source
#1Jan Werner (University of Cologne)H-Index: 1
#1Jan-Michael Werner (University of Cologne)H-Index: 7
Last. Norbert GalldiksH-Index: 46
view all 20 authors...
Background: The CeTeG/NOA-09 phase-III trial demonstrated a significant survival benefit of lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients with methylated O6-methylguanine-DNA methyltransferase promoter. Following lomustine-temozolomide chemoradiation, late and prolonged pseudoprogression may occur. We here evaluated the value of amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (FET) for differentiating pseudoprogression from tumor progression. Methods: We r...
Source
#1Norbert Galldiks (University of Cologne)H-Index: 46
#2Diana S.Y. Abdulla (University of Cologne)H-Index: 5
Last. Cornelia Mauch (University of Cologne)H-Index: 60
view all 25 authors...
Purpose: We investigated the value of O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastases (BM) since contrast-enhanced MRI often remains inconclusive. Methods: We retrospectively identified 40 patients with 107 BM secondary to melanoma (n = 29 with 75 BM) or non-small cell lung cancer (n = 11 with 32 BM) treated with ICI or TT who had 18F...
3 CitationsSource
#1Philipp LohmannH-Index: 17
#2Norbert Galldiks (University of Cologne)H-Index: 46
Last. Karl-Josef LangenH-Index: 60
view all 10 authors...
Abstract Over the last years, the amount, variety, and complexity of neuroimaging data acquired in patients with brain tumors for routine clinical purposes and the resulting number of imaging parameters have substantially increased. Consequently, a timely and cost-effective evaluation of imaging data is hardly feasible without the support of methods from the field of artificial intelligence (AI). AI can facilitate and shorten various time-consuming steps in the image processing workflow, e.g., t...
10 CitationsSource
#1Jan Werner (University of Cologne)H-Index: 1
#1Jan-Michael Werner (University of Cologne)H-Index: 7
Last. Norbert Galldiks (University of Cologne)H-Index: 46
view all 18 authors...
Background: The CeTeG/NOA-09 phase-III trial demonstrated a significant survival benefit of lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients with methylated O6-methylguanine-DNA methyltransferase promoter. Following lomustine-temozolomide chemoradiation, late and prolonged pseudoprogression may occur. We here evaluated the value of amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (FET) for differentiating pseudoprogression from tumor progression. Methods: We r...
Source